The global antacids market size reached US$ 6.7 Billion in 2022. Looking forward, the publisher expects the market to reach US$ 8.6 Billion by 2028, exhibiting a growth rate (CAGR) of 4% during 2023-2028.
Antacids are over-the-counter (OTC) medications that neutralize the acid in the stomach to relieve indigestion and heartburn. They contain ingredients such as sodium bicarbonate, aluminum, magnesium hydroxide, and calcium and are commonly available in convenient chewable tablets, powder, and liquid forms. Antacids are widely used for treating sore stomach, dyspepsia discomfort, stomach ulcers, inflammation, acid indigestion, and stomach upset. Acid neutralizers, promotility agents, and proton pump inhibitors are common drugs that weaken the acid in the stomach. They assist in protecting the stomach lining from the duodenum, esophagus, and harsh acids released while eating. They are self-prescribed medications and act by neutralizing the acid in the stomach and inhibiting pepsin.
Antacids are over-the-counter (OTC) medications that neutralize the acid in the stomach to relieve indigestion and heartburn. They contain ingredients such as sodium bicarbonate, aluminum, magnesium hydroxide, and calcium and are commonly available in convenient chewable tablets, powder, and liquid forms. Antacids are widely used for treating sore stomach, dyspepsia discomfort, stomach ulcers, inflammation, acid indigestion, and stomach upset. Acid neutralizers, promotility agents, and proton pump inhibitors are common drugs that weaken the acid in the stomach. They assist in protecting the stomach lining from the duodenum, esophagus, and harsh acids released while eating. They are self-prescribed medications and act by neutralizing the acid in the stomach and inhibiting pepsin.
Antacids Market Trends:
The increasing prevalence of gastroesophageal reflux diseases (GERD) is one of the key factors driving the growth of the market. Antacids are widely used as they are cost-effective and assist in relieving inflammation, swelling, pain, and irritation associated with heartburn. In line with this, changing lifestyles, such as irregular dietary habits, sleep patterns, and sedentary lifestyles, is positively impacting the market growth. Moreover, various product innovations, such as the development of raft-forming antacids that are safe and strong medications that provide higher efficacy and increased duration of action, are providing an impetus to the market growth. Additionally, the widespread adoption of chewable tables in different flavors that are easy to store, provide the correct amount of dosage, and improve patient adherence is favoring the market growth. Other factors, such as the rising geriatric population that are prone to acidic complications, easy product availability through e-commerce platforms, and the increasing prevalence of heartburn among the masses, are creating a positive outlook for the market.Key Market Segmentation:
The publisher provides an analysis of the key trends in each sub-segment of the global antacids market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on drug class, formulation type and distribution channel.Breakup by Drug Class:
- Proton Pump Inhibitors
- H2 Antagonist
- Acid Neutralizers
- Pro-Motility Agents
Breakup by Formulation Type:
- Tablet
- Liquid
- Powder
- Others
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Others
Breakup by Region:
North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline plc, Johnson & Johnson, Pfizer Inc., Procter & Gamble Company, Reckitt Benckiser Group PLC, Sanofi S.A., Sun Pharmaceutical Industries Ltd. and Takeda Pharmaceutical Company Limited.Key Questions Answered in This Report:
- How has the global antacids market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global antacids market?
- What are the key regional markets?
- What is the breakup of the market based on the drug class?
- What is the breakup of the market based on the formulation type?
- What is the breakup of the market based on the distribution channel?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global antacids market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface3 Executive Summary11 Value Chain Analysis13 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Antacids Market
6 Market Breakup by Drug Class
7 Market Breakup by Formulation Type
8 Market Breakup by Distribution Channel
9 Market Breakup by Region
10 SWOT Analysis
12 Porters Five Forces Analysis
14 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Abbott Laboratories
- AstraZeneca plc
- Bayer AG
- Boehringer Ingelheim International GmbH
- Dr. Reddy’s Laboratories Ltd.
- GlaxoSmithKline plc
- Johnson & Johnson
- Pfizer Inc.
- Procter & Gamble Company
- Reckitt Benckiser Group PLC
- Sanofi S.A.
- Sun Pharmaceutical Industries Ltd. and Takeda Pharmaceutical Company Limited.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 143 |
| Published | May 2023 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 6.7 Billion |
| Forecasted Market Value ( USD | $ 8.6 Billion |
| Compound Annual Growth Rate | 4.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 12 |
